

Daniel Jenkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8659340/publications.pdf>

Version: 2024-02-01

20
papers

11,807
citations

566801

15
h-index

752256

20
g-index

24
all docs

24
docs citations

24
times ranked

17766
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. <i>Cell</i> , 2022, 185, 467-484.e15.	13.5	788
2	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .	2.3	26
3	Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2022, 40, 5248-5262.	1.7	9
4	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. <i>EBioMedicine</i> , 2022, 81, 104128.	2.7	8
5	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
6	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
7	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
8	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
9	Safety and Immunogenicity of Adenovirus and Poxvirus Vected Vaccines against a Mycobacterium Avium Complex Subspecies. <i>Vaccines</i> , 2021, 9, 262.	2.1	3
10	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
11	A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. <i>Nature Communications</i> , 2021, 12, 4636.	5.8	31
12	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV,the</i> , 2021, 8, e474-e485.	2.1	190
13	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
14	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
15	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
16	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38
17	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
18	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196

#	ARTICLE	IF	CITATIONS
19	Is it time to consider IgG4-related disease in idiopathic retroperitoneal fibrosis?. Journal of Clinical Urology, 2017, 10, 222-224.	0.1	0
20	Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222). SSRN Electronic Journal, 0, , .	0.4	23